CN Patent

CN113181161A — 药物组合物、治疗方法及其用途

Assigned to Boehringer Ingelheim International GmbH · Expires 2021-07-30 · 5y expired

What this patent protects

本发明涉及用于在患者中治疗、预防、防止慢性肾病和/或延迟其进展的具体SGLT‑2抑制剂，所述患者例如为患有前驱糖尿病、1型或2型糖尿病的患者。

USPTO Abstract

本发明涉及用于在患者中治疗、预防、防止慢性肾病和/或延迟其进展的具体SGLT‑2抑制剂，所述患者例如为患有前驱糖尿病、1型或2型糖尿病的患者。

Drugs covered by this patent

Patent Metadata

Patent number
CN113181161A
Jurisdiction
CN
Classification
—
Expires
2021-07-30
Drug substance claim
No
Drug product claim
No
Assignee
Boehringer Ingelheim International GmbH
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.